Recruiting Multiple Myeloma Studies in Maitland
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP)....
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP....
About Multiple Myeloma Clinical Trials in Maitland
Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.
There are currently 2 multiple myeloma clinical trials recruiting participants in Maitland, FLORIDA. These studies are seeking a combined 642 participants. Research is being sponsored by Dianthus Therapeutics, Immunovant Sciences GmbH. Clinical trial participation is free and participants receive study-related medical care at no cost.
Multiple Myeloma Clinical Trials in Maitland — FAQ
Are there multiple myeloma clinical trials in Maitland?
Yes, there are 2 multiple myeloma clinical trials currently recruiting in Maitland, FLORIDA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Maitland?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Maitland research site will contact you about next steps.
Are clinical trials in Maitland free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Maitland studies also compensate for your time and travel.
What multiple myeloma treatments are being tested?
The 2 active trials in Maitland are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.
Data updated March 2, 2026 from ClinicalTrials.gov